Shelby Knowles / Bloomberg via Getty Images Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for sleep apnea last month. Weight loss ...

And now they're doing it without their best pass blocker in Elgton Jenkins. The two-time Pro Bowl tackle/guard needed help in getting off the field after suffering a stinger after getting a shot ...

In the case of Eli Manning, you cannot. And while Peyton’s overall career might be better, Eli got a leg up on older brother when he won his second Super Bowl MVP following the 2011 season ...

Every year, a new list of players is inducted, and this time, there are 15 finalists left, including former New York Giants quarterback Eli Manning, who is attempting to make it in his first year ...

It’s been two years since Mick Jenkins last released a new album, 2023’s The Patience. Given he’s released albums at a clip of just about every two years, that means he more than likely ...

Correction: This article initially misstated the nature of Jenkins' 2013 bid for county executive. He sought the Democratic endorsement at a party convention but didn't run in a primary afterward.

Chicago Bears left guard Teven Jenkins is undeniably talented. He's a downright nasty bully in the run game and has been one of the Bears' better starting offensive linemen over the last four ...

Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in upfront and near-term payments for global rights to an asset that is ...

SAN FRANCISCO — Eli Lilly CEO Dave Ricks on Tuesday said he believed the company could find “significant common cause” with the incoming Trump administration, including on issues around ...

Investing.com -- Eli Lilly and Company (NYSE:LLY) has projected its full-year global revenue for 2024 to reach around $45 billion, marking a 32% increase from the prior year. The company also ...

Jan 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to expand its pipeline of ...

Eli Lilly (LLY) revised its revenue outlook on Tuesday for the fourth quarter of 2024 on weaker-than-expected demand for its popular weight-loss drugs, Zepbound and Mounjaro. The drugmaker said it ...